Source comparison
CJC-1295 no DAC Muscle Growth Complete Guide 2026: Comparison Analysis
Before selecting a growth hormone secretagogue for muscle research, understanding the mechanistic and practical differences between available peptides is critical. CJC-1295 no DAC 30 minutes Sharp transient pulse (2–3 hours elevated GH) 3–4× weekly, pre-traini
This comparison does not assign a generated winner or score.
- Before selecting a growth hormone secretagogue for muscle research, understanding the mechanistic and practical differences between available peptides is critical.
- CJC-1295 no DAC
- 30 minutes
- Sharp transient pulse (2–3 hours elevated GH)
- 3–4× weekly, pre-training
- Mimics natural pulsatile signaling; minimal receptor downregulation
- Preferred for muscle hypertrophy research due to physiological pulse pattern and training-synced IGF-1 windows
- CJC-1295 with DAC
- 6–8 days
- Sustained elevation (blunted peaks, elevated baseline)
- 1–2× weekly
- Chronic supraphysiological GH; GHRH receptor desensitization after 8–12 weeks
- Useful for long-term IGF-1 elevation but loses pulsatile advantage; not ideal for training-specific anabolism
- GHRP-2 / GHRP-6
- 20–30 minutes
- Moderate pulse (150–200% GH increase)
- Daily or twice daily
- Ghrelin receptor agonist; stimulates appetite significantly
- Strong GH pulse but appetite side effects complicate lean mass research; often stacked with CJC no DAC
- Ipamorelin
- 2 hours
- Gentle pulse (100–150% GH increase)
- Daily
- Minimal ghrelin activity; no appetite stimulation
- Weakest GH pulse but excellent tolerability; suboptimal for maximal hypertrophy endpoints
- Hexarelin
- Very strong pulse (300–500% GH increase)
- 2–3× weekly maximum
- Rapid desensitization; cortisol and prolactin elevation
- Potent but unsustainable; receptor downregulation within 4–6 weeks limits research utility
- The no-DAC variant's short half-life is a feature, not a limitation. It preserves the ultradian rhythm that skeletal muscle evolved to respond to, rather than imposing a pharmacological override that the endocrine system adapts against.